(Q38192972)

30 August 2017

1 reference

title

Transforming growth factor-beta and its implication in the malignancy of gliomas (English)

1 reference

30 August 2017

3

David Fortin

1 reference

30 August 2017

Laurent-Olivier Roy

1

1 reference

30 August 2017

Marie-Belle Poirier

series ordinal

2

1 reference

30 August 2017

publication date

5 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

1-14

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-014-0308-y

30 August 2017

exact match

0 references

cites work

Role of transforming growth factor beta in human disease

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Genealogy, expression, and cellular function of transforming growth factor-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Transforming growth factor-{beta}-inducible phosphorylation of Smad3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-beta signaling: positive and negative effects on tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

21 January 2018

On the origin of glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Mosaic analysis with double markers reveals tumor cell of origin in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Chemoresistance of glioblastoma cancer stem cells--much more complex than expected

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Processing of transforming growth factor beta 1 precursor by human furin convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Transforming growth factor-beta (TGF-beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Roles for the type III TGF-beta receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Transcriptional control by the TGF-beta/Smad signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGFbeta signaling in growth control, cancer, and heritable disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Cyclin-dependent kinases regulate the antiproliferative function of Smads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

USP15 is a deubiquitylating enzyme for receptor-activated SMADs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Key role for ubiquitin protein modification in TGFβ signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Non-Smad TGF-beta signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Non-Smad signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Non-Smad pathways in TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The role of transforming growth factor beta in glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Molecular pathogenesis of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Cell biology: Developmental predisposition to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

DNA repair and resistance of gliomas to chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The role of integrins in the malignant phenotype of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Targeting the tumour vasculature: insights from physiological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The cell biology of the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Basic principles of immunological surveillance of the normal central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

All in the head: obstacles for immune rejection of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous p

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Induction of bystander response in human glioma cells using high-energy electrons: a role for TGF-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Lysosomotropic drugs inhibit maturation of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Furin at the cutting edge: from protein traffic to embryogenesis and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

The blood-brain barrier: its influence in the treatment of brain tumors metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Drug delivery and nanoparticles:applications and hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Nanoparticles as drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Malignant glioma: should chemotherapy be overthrown by experimental treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Isolation and characterization of human malignant glioma cells from histologically normal brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Quality of life in neurooncology--age matters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0308-Y

Mechanisms of malignant glioma immune resistance and sources of immunosuppression

21 January 2018

1 reference

12 December 2020

Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours

1 reference

12 December 2020

Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase.

1 reference

12 December 2020

Identification of the glioma cell of origin.

1 reference

12 December 2020

High levels of Id1 expression define B1 type adult neural stem cells

1 reference

12 December 2020

Ubiquitin removal in the TGF-β pathway

1 reference

12 December 2020

Effect of transforming growth factor-beta on early and late activation events in human T cells

1 reference

12 December 2020

TGF beta signalling and its role in tumour pathogenesis

1 reference

12 December 2020

Some considerations for the study of TGFbeta in medium of irradiated T98G cells: activation, release and consumption.

1 reference

12 December 2020

Specific chromosomal abnormalities in malignant human gliomas.

1 reference

12 December 2020

Expression of TGF-beta isoforms during first trimester human embryogenesis.

1 reference

12 December 2020

Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis

1 reference

12 December 2020

Identification of a cancer stem cell in human brain tumors

1 reference

12 December 2020

Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta

1 reference

12 December 2020

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer

1 reference

12 December 2020

Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1

1 reference

12 December 2020

Transcriptional regulation of the A and B chain genes of platelet-derived growth factor in microvascular endothelial cells.

1 reference

12 December 2020

T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors.

1 reference

12 December 2020

Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors.

1 reference

12 December 2020

Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia

1 reference

12 December 2020

Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro

1 reference

12 December 2020

USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor

1 reference

12 December 2020

10.1007/S11523-014-0308-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1033056945

0 references

1 reference